Early and Sustained Elevation in Serum Pancreatic Amylase Activity: A Novel Predictor of Morbidity after Pancreatic Surgery.
Published on Apr 30, 2021in Annals of Surgery10.13
· DOI :10.1097/SLA.0000000000004921
OBJECTIVE To characterize early postoperative serum pancreatic amylase (spAMY) trends after pancreatic resections. SUMMARY BACKGROUND DATA A postoperative spAMY elevation is a common finding but uncertainties remain about its meaning and prognostic implications. METHODS Analysis of patients who consecutively underwent pancreatectomy from 2016 to 2019. spAMY activity was assessed from postoperative day (POD) 0 to 3. Different patterns of spAMY have been identified based on the spAMY standard range (10-52 U/l). RESULTS Three patterns were identified: (#1) spAMY values always upper limit of normal at any POD; (#2) Sustained increase in spAMY activity on POD 0 + 1; (#3) Sustained increase in spAMY activity including POD 1 + 2. Shifting through spAMY patterns was associated with increase morbidity (21% in #1 to 68% in #3 at POD 7; log rank 3-times or >the spAMY normal limit (p = 0.85). POPF (9% in #1 vs. 48% in #3, p< 0.001) progressively increased across patterns. Pre-operative diabetes (OR 0.19), neoadjuvant therapy (OR 0.22), pancreatic texture (OR 8.8), duct size (OR 0.78), and final histology (OR 2.2) were independent predictors of pattern #3. CONCLUSIONS A sustained increase in spAMY activity including POD 1 + 2 (#3) represents an early postoperative predictor of overall and severe early morbidity. An early and dynamic evaluation of spAMY could crucially impact the subsequent clinical course with relevant prognostic implications.